Attenuated GLP-1 secretion in obesity: cause or consequence
Open accessAbstract
BACKGROUND: Hypersecretion of insulinotropic factors such as glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(7-36)amide (GLP-1) have been postulated to account for the hyperinsulinaemia of obesity. AIMS: To examine the role of GLP-1 and GIP in obese women and matched controls. SUBJECTS: Six lean and six obese women subjects matched for age. METHODS: The gut hormone, plasma glucose, and serum triglyceride responses were studied over 180 minutes after oral carbohydrate and fat meals. Heparin (10,000 units) was given intravenously at 120 minutes. RESULTS: There was pronounced attenuation of plasma GLP-1 secretion to oral carbohydrate in the obese compared with lean subjects but no such difference in response to oral fat load. There were no differences in the plasma GIP responses to carbohydrate or fat feeding. There was an apparent fall in plasma GLP-1 values in all subjects after administration of heparin. CONCLUSION: Postprandial GLP-1 secretion in response to oral carbohydrate is considerably attenuated in obese subjects. The cause of this attenuation of GLP-1 secretion is not known although we suggest that both this fall and the overall reduction in GLP-1 values in obese subjects may be related to an increase in plasma non-esterified fatty acids.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The decrease of GLP-1 in obese subjects may be related to increased plasma non-esterified fatty acids (NEFA).
“Ranganath (22) et al. believe that the decrease of GLP-1 in obese subjects may be related to increased plasma non-esterified fatty acids (NEFA).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · see citing works
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · see citing works
New Interpretation of Oral Glucose Tolerance
Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738 · see citing works
Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695 · see citing works
Self-citationHamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649 · see citing works
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Nielsen, O. V., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 611 · see citing works
Exon duplication and divergence in the human preproglucagon gene
Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593 · see citing works
Ørskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 318 · see citing works
Mordes, J. P., & Rossini, A. A. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90772-5 · Cited by 217 · see citing works
Plasma free fatty acid turnover rate in obesity
Björntorp, P., Bergman, H., & Varnauskas, E. (1969) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1969.tb07347.x · Cited by 161 · see citing works
Nutrient regulation of insulin secretion
Matthews, E. K. (1993) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(93)90100-s · Cited by 147 · see citing works
Radioimmunoassay of Gastric Inhibitory Polypeptide
Morgan, L., Morris, B., & Marks, V. (1978) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456327801500138 · Cited by 122 · see citing works
Self-citation大村, 裕. (1991) · Medical Entomology and Zoology · Cited by 86 · see citing works
Zunz, E., & Jean, L. B. (1929) · Archives Internationales de Physiologie · doi:10.1080/13813455.1929.11864670 · Cited by 80 · see citing works
Fukase, N., Igarashi, M., Takahashi, H., Manaka, H., Yamatani, K., Daimon, M., Tominaga, M., & Sasaki, H. (1993) · Diabetic Medicine · doi:10.1111/j.1464-5491.1993.tb01995.x · Cited by 69 · see citing works
The Enteroinsular Axis Revisited
Ensinck, J. W., & D’Alessio, D. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262009 · Cited by 24 · see citing works
The C-peptide of proinsulin: Its diagnostic use and a possible physiological role.
Hampton, S. M. (1983) · Surrey Research Insight Open Access (The University of Surrey) · Cited by 18 · see citing works
Beety, J. M. (1994) · Surrey Research Insight Open Access (The University of Surrey) · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · see citing works
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · see citing works
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · see citing works
Laferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J. R., Colarusso, A., Kovack, B., Bawa, B., Koshy, N., Lee, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2851 · Cited by 682 · see citing works
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · see citing works
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468 · see citing works
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · see citing works
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442 · see citing works
Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434 · see citing works
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · see citing works
Morínigo, R., Moizé, V., Musri, M., Lacy, A. M., Navarro, S., Marín, J. L., Delgado, S., Casamitjana, R., & Vidal, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0904 · Cited by 397 · see citing works
Hormonal regulation of food intake
Stanley, S., Wynne, K., McGowan, B., & Bloom, S. (2005) · Physiological Reviews · doi:10.1152/physrev.00015.2004 · Cited by 372 · see citing works
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
Cena, H., Chiovato, L., & Nappi, R. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa285 · Cited by 356 · see citing works
Vulevic, J., Juric, A., Tzortzis, G., & Gibson, G. R. (2013) · The Journal of Nutrition · doi:10.3945/jn.112.166132 · Cited by 349 · see citing works
Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321 · see citing works
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288 · see citing works
Inter-organ cross-talk in metabolic syndrome
Priest, C., & Tontonoz, P. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0145-5 · Cited by 279 · see citing works
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248 · see citing works
GLP-1 and energy balance: an integrated model of short-term and long-term control
Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220 · see citing works
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146 · see citing works
Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126 · see citing works
Obesity-associated biomarkers and executive function in children
Miller, A. L., Lee, H. J., & Lumeng, J. C. (2015) · Pediatric Research · doi:10.1038/pr.2014.158 · Cited by 122 · see citing works
A functional neuroimaging review of obesity, appetitive hormones and ingestive behavior
Burger, K. S., & Berner, L. A. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.04.025 · Cited by 110 · see citing works
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94 · see citing works
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93 · see citing works
The Emerging Role of Polyphenols in the Management of Type 2 Diabetes
Wang, Y., Alkhalidy, H., & Liu, D. (2021) · Molecules · doi:10.3390/molecules26030703 · Cited by 88 · see citing works
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84 · see citing works
What is GLP-1 really doing in obesity?
Hira, T., Pinyo, J., & Hara, H. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.09.003 · Cited by 74 · see citing works
Investigation of the long-term sustainability of changes in appetite after weight loss
Nymo, S., Coutinho, Sr., Eknes, P., Vestbostad, I., Rehfeld, J., Truby, H., Kulseng, B., & Martins, C. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0119-9 · Cited by 68 · see citing works
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58 · see citing works
Liraglutide restores impaired associative learning in individuals with obesity
Hanssen, R., Rigoux, L., Kuzmanovic, B., Iglesias, S., Kretschmer, A. C., Schlamann, M., Albus, K., Edwin Thanarajah, S., Sitnikow, T., Melzer, C., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00859-y · Cited by 52 · see citing works
Incretin Hormones, Obesity and Gut Microbiota
Angelini, G., Russo, S., & Mingrone, G. (2024) · Peptides · doi:10.1016/j.peptides.2024.171216 · Cited by 47 · see citing works
RANGANATH, L., NORRIS, F., MORGAN, L., WRIGHT, J., & MARKS, V. (1999) · Clinical Science · doi:10.1042/cs0960335 · Cited by 47 · see citing works
Self-citationUnlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30 · see citing works
MARUYAMA, C., KIKUCHI, N., MASUYA, Y., HIROTA, S., ARAKI, R., & MARUYAMA, T. (2013) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.59.264 · Cited by 29 · see citing works
Mechanisms behind GLP-1 induced weight loss
Larsen, P. J. (2008) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/1474651408100525 · Cited by 28 · see citing works
Potential use of exenatide for the treatment of obesity
Folli, F., & Guardado Mendoza, R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.630660 · Cited by 26 · see citing works
Obesity and Exercise: New Insights and Perspectives
James, N. M., & Stanford, K. I. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf017 · Cited by 20 · see citing works
Blundell, J. E., Finlayson, G., & Halford, J. C. G. (2009) · Clinical Obesity in Adults and Children · doi:10.1002/9781444307627.ch11 · Cited by 1 · see citing works
- Authors
- Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V
- Affiliations
- University of Surrey (GB)
- Venue
- Gut
- Publisher
- BMJ
- Published
- 1996-06
- Volume
- 38
- Issue
- 6
- Pages
- 916-919
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC1383202
- OpenAlex
- W2158803184
- Cited by
- 394
- References
- 19
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 15 · 2023: 9 · 2022: 14 · 2021: 14 · 2020: 14 · 2019: 18 · 2018: 11 · 2017: 15 · 2016: 11 · 2015: 17 · 2014: 26 · 2013: 23 · 2012: 12
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gut (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, obesity, hyperinsulinemia, postprandial hormone secretion, heparin, free fatty acids, oral glucose tolerance
- MeSH terms
- Adult, Dietary Carbohydrates, Dietary Fats, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glucagon, Heparin, Humans, Obesity, Peptide Fragments, Radioimmunoassay, Case-Control Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
